DEPDC1: Potential Drug Target and Biomarker (G55635)

Target Name: DEPDC1

NCBI ID: G55635

DEPDC1

DEPDC1: Potential Drug Target and Biomarker

DEPDC1 (DEP Domain-Protein-Domain interactions and PDGF signaling pathway) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the PDGF signaling pathway, which is a well-established mechanism of cell proliferation and survival signaling in many organisms. The PDGF signaling pathway is characterized by the presence of a phosphorylated tyrosine residue, which serves as a target for various signaling molecules, including the protein DEPDC1.

The DEPDC1 protein is composed of 115 amino acid residues and has a calculated molecular mass of 13.9 kDa. It is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract, and is highly conserved across different species. The DEPDC1 protein is localized to the endoplasmic reticulum (ER) and can be released from the ER through the process of endocytosis. Once released, DEPDC1 can interact with various protein partners, including the protein PDGF-B.

PDGF signaling is a complex process that involves the exchange of information between cells through the production and deployment of signaling proteins. In the case of DEPDC1, it is unclear what the precise function of this protein is, but it is likely involved in some aspect of the regulation of cell proliferation and survival. There are several potential drug targets that have been identified in the DEPDC1 gene, including DEPDC1 itself, its splice variant DEPDC1 variant 2, and its gene product, PDGF-B.

The most promising potential drug target for DEPDC1 is its splice variant, DEPDC1 variant 2. This variant has an additional 24 amino acid residues compared to the standard DEPDC1 protein, and is known to have altered localization and stability. It is possible that DEPDC1 variant 2 may play a more important role in the regulation of cell proliferation and survival than the standard DEPDC1 protein, making it an attractive target for drug development.

In addition to its potential as a drug target, DEPDC1 is also a potential biomarker for certain diseases. The PDGF signaling pathway is involved in the regulation of cell proliferation and survival, and alterations in this pathway have been implicated in a number of diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, DEPDC1 and its variants may be useful for the diagnosis and treatment of these diseases.

In conclusion, DEPDC1 is a protein that is expressed in various tissues of the body and is involved in the PDGF signaling pathway. Its splice variant, DEPDC1 variant 2, is a potential drug target and biomarker for the regulation of cell proliferation and survival. Further research is needed to fully understand the function of DEPDC1 and its variants, and to determine their utility as drug targets and biomarkers for various diseases.

Protein Name: DEP Domain Containing 1

Functions: May be involved in transcriptional regulation as a transcriptional corepressor. The DEPDC1A-ZNF224 complex may play a critical role in bladder carcinogenesis by repressing the transcription of the A20 gene, leading to transport of NF-KB protein into the nucleus, resulting in suppression of apoptosis of bladder cancer cells

The "DEPDC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEPDC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets